Piramal Critical Care and BrePco Biopharma received UK approval for Neoatricon, a paediatric Dopamine Hydrochloride solution. This innovation addresses a gap for neonates and children by ensuring ...

A calculation error related to the Rule of 6 may have contributed to an infant's death recently when it led to a misplaced decimal point and the preparation of a ...

Onapgo is a wearable subcutaneous (SC) infusion device that delivers apomorphine, a non-ergoline dopamine agonist, on a continuous basis. Apomorphine is believed to treat “off” episodes ...

Fourth, we looked at how the resulting infusion rates would affect fluid requirements in patients of various weights. All the commercial premixes of dobutamine and dopamine are available in 5% ...

Developed by Ireland-based BrePco Biopharma, Neoatricon is the first paediatric-strength dopamine hydrochloride infusion for treating hypotension in neonates, infants, and children. Shares of Piramal ...

Piramal Critical Care has reserved commercialisation rights for the EU, UK, and Norway and will look after Neoatricon in ...

Piramal Critical Care, a part of Piramal Pharma, and Ireland-based BrePco Biopharma have received marketing approval from the ...

Piramal Critical Care and BrePco Biopharma have secured UK approval for Neoatricon, a medication for low blood pressure and heart rate in children, addressing a critical gap in paediatric care.